Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30958645 | 1.00 | PIK3CD (0.52) | PIK3CDPIK3CAGFERKMT2ACNR1 | |
| SCHEMBL29933707 | 0.89 | IDO1 (0.57) | PIK3CDPIK3CAGFERCNR1USP30 | |
| SCHEMBL28834220 | 0.89 | IDO1 (0.57) | PIK3CDPIK3CAGFERCNR1USP30 | |
| SCHEMBL28834221 | 0.89 | IDO1 (0.57) | PIK3CDPIK3CAGFERCNR1USP30 | |
| SCHEMBL28833982 | 0.89 | CNR1 (0.55) | PIK3CDPIK3CAKMT2ACNR1USP30 | |
| SCHEMBL29933511 | 0.89 | CNR1 (0.55) | PIK3CDPIK3CAKMT2ACNR1USP30 | |
| SCHEMBL28834193 | 0.89 | PIK3CD (0.55) | PIK3CDPIK3CACNR1USP30IDO1 | |
| SCHEMBL28834195 | 0.89 | PIK3CD (0.55) | PIK3CDPIK3CACNR1USP30IDO1 | |
| SCHEMBL29933647 | 0.89 | PIK3CD (0.55) | PIK3CDPIK3CACNR1USP30IDO1 | |
| SCHEMBL28834189 | 0.87 | USP30 (0.52) | PIK3CDPIK3CACNR1USP30IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | PIK3CD 641/4885PIK3CA 440/4885GFER 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.